Welcome to our dedicated page for Dalrada Financl news (Ticker: DFCO), a resource for investors and traders seeking the latest updates and insights on Dalrada Financl stock.
Dalrada Financial Corporation (DFCO), now identified in company communications as Dalrada Technology Group, Inc., generates news across clean energy, semiconductor deposition technology, precision manufacturing, and health care. Its press releases highlight developments within core segments such as Dalrada Climate Technology, Deposition Technology (Deptec), and Genefic Specialty Pharmacy.
News related to clean energy and climate technology often covers contracts, distribution agreements, and facility developments involving Dalrada’s heat pump technology. Examples include agreements for heat pump installations in European light industrial facilities and a master distribution agreement in the United States that targets sales of commercial and residential heat pump units across multiple regions.
Updates from Deposition Technology (Deptec) focus on advanced thin-film deposition and semiconductor-related tools. Company announcements have detailed the availability of the proprietary Spectroptix plasma spectrometer for advance ordering, as well as the establishment of a manufacturing and R&D facility in Portland, Oregon, to support deposition technology production and sales in North America and beyond.
In the health care segment, news frequently centers on Genefic, Inc. and Genefic Specialty Pharmacy. Communications include interviews and updates that describe revenue growth, expansion of specialty pharmacy services, and the operation of licensed diagnostic laboratories and an infusion pharmacy.
Dalrada’s news flow also includes corporate and governance updates, such as changes to its board of directors, executive appointments, and the selection of independent registered public accounting firms. Together, these items provide insight into the company’s strategic direction, operational focus, and corporate evolution from Dalrada Financial Corporation (DFCO) to Dalrada Technology Group, Inc. (DHTI).
Dalrada Financial (OTCQB:DFCO) announced that its Chairman and CEO, Brian Bonar, has been named the 2024 CEO of the Year by the San Diego Business Journal (SDBJ) for Dalrada's business category. The award was presented at a special ceremony in Torrey Pines, San Diego.
Bonar was recognized for his individual work and leadership, which has led to Dalrada making significant impacts in climate technology and healthcare. The company focuses on developing advanced solutions such as commercial and home heat pumps, as well as providing accessible healthcare and specialty pharmaceuticals.
This recognition highlights Bonar's commitment to solving global challenges and driving Dalrada's growth both locally and globally. The award and feature in SDBJ's special edition further solidify Dalrada's position as an innovative leader in its field.
Dalrada Financial (OTCQB:DFCO) CEO Brian Bonar shared insights and updates in a new interview with SmallCapVoice. Key highlights include:
- Bonar's CEO of the Year Award from San Diego Business Journal
- Opportunities in New York City due to Local Law 97
- Dalrada's appointment to the Minority Business RoundTable (MBRT)
Bonar discussed the potential impact of NYC's Local Law 97, which aims to reduce greenhouse gas emissions in buildings. He noted that Dalrada's heat pump technology could capture a significant market share in replacing gas boilers, potentially generating $60 million in revenue over 18 months with just 1% market penetration. Bonar also anticipates revenue from government opportunities through MBRT starting in the first quarter of next year.
Dalrada Financial (OTCQB: DFCO) has been invited to join the Minority Business RoundTable (MBRT), a prestigious nonprofit organization led by Roger Campos. This membership allows Dalrada unique access to business opportunities in public, private, and government sectors, enhancing its influence and reach globally. Dalrada’s gold-level sponsorship underscores its commitment to a lasting partnership with MBRT. CEO Brian Bonar highlighted the potential for increased awareness and credibility among policymakers, while Campos praised Dalrada's innovative contributions to local and global economies. This strategic move aligns with Dalrada's mission to effect positive change through its technological solutions in climate and healthcare.
Dalrada Financial (OTCQB: DFCO) announced that its healthcare subsidiary, Genefic, has acquired IV Services, , a leading pharmaceutical and infusion management company. This acquisition strengthens Genefic’s market position by expanding its sales and operational footprint, increasing top-line revenue, and enhancing patient care capabilities. The acquisition is non-dilutive to shareholders and allows Genefic to enter the $42 billion global infusion pharmacy management market, which is expected to grow to $70 billion by 2030. Genefic gains new regional presence in Louisiana and Mississippi, complementing its existing operations in several other U.S. states.
Dalrada Financial (OTCQB: DFCO) filed a Form 10-Q for Q3 2024, revealing a revenue of $10.3 million, driven primarily by its pharmaceutical subsidiary, Genefic Specialty Pharmacy. Genefic accounted for $8.6 million, an 80% increase from Q3 2023 and a 95.5% rise from the previous quarter. The company also converted $13.3 million of affiliate debt to Series I preferred shares, reducing net losses to $2.9 million, the lowest since 2021. CEO Brian Bonar emphasized ongoing efforts to clear debt and reduce expenditures, with a net equity of $8.8 million. Dalrada anticipates continued growth in Q4 and a year-over-year revenue increase by the end of fiscal 2024.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
FAQ
What is the current stock price of Dalrada Financl (DFCO)?
What is the market cap of Dalrada Financl (DFCO)?
